Integrating Companion Diagnostics into Precision Oncology Trials

What Are Companion Diagnostics and Why They Matter

Companion diagnostics (CDx) are in vitro diagnostic devices or imaging tools essential for the safe and effective use of a corresponding therapeutic product. In oncology, CDx testing is often the gateway to trial enrollment—patients must meet specific biomarker-defined eligibility criteria before receiving the investigational drug. For example, a HER2-targeted therapy requires HER2 amplification confirmation, an EGFR inhibitor needs exon 19 deletions or L858R mutations, and an ALK inhibitor demands ALK rearrangement detection.

The role of CDx is not only to identify patients most likely to benefit but also to exclude those at higher risk of adverse effects. Regulators like the FDA and EMA mandate that, when biomarker-based eligibility is critical, the diagnostic must be validated to the same standard of evidence as the drug itself. This concept is central to precision oncology: the therapy’s approval can be contingent on having an approved CDx available.

Real-world example: Trastuzumab deruxtecan was approved alongside a specific HER2 testing method with defined scoring cutoffs. Without an approved HER2 IHC or ISH assay, trial enrollment would not have been possible. Similarly, osimertinib’s label specifies that only EGFR T790M-positive patients by an FDA-approved test are eligible post-EGFR-TKI resistance.

Regulatory Expectations: FDA, EMA, and Global Considerations

From a regulatory standpoint, companion diagnostics are considered high-risk (Class III in the US, Class C under IVDR in the EU) because incorrect results can lead to inappropriate treatment. The FDA’s guidance “In Vitro Companion Diagnostic Devices” specifies that CDx must demonstrate both analytical and clinical validation. Analytical validation ensures that the assay reliably and reproducibly measures the biomarker; clinical validation confirms the biomarker’s predictive value in identifying patients who will benefit from the therapy.

In the EU, under the IVDR (Regulation (EU) 2017/746), companion diagnostics must be assessed by a notified body and involve consultation with a competent medicines authority, such as the EMA. This adds complexity and timelines, especially for global oncology trials seeking simultaneous approval in multiple jurisdictions. Countries like Japan, China, and Australia have their own specific regulatory frameworks, and harmonizing CDx approvals can be a major operational challenge.

One frequent pitfall in global trials is assuming that a US-approved CDx automatically meets EU or APAC requirements—it often does not. This requires early regulatory strategy alignment between drug and diagnostic development teams, ideally before pivotal trial protocol finalization.

Analytical Validation: Establishing Assay Performance (LOD, LOQ, and More)

Analytical validation parameters for CDx include sensitivity, specificity, limit of detection (LOD), limit of quantitation (LOQ), reproducibility, and robustness. For example, a ctDNA-based assay for detecting EGFR T790M may need an LOD of 0.2% variant allele frequency (VAF) with ≥95% confidence to ensure that eligible patients are not missed. LOQ might be set at 0.5% VAF to ensure reliable quantitation for therapy decision-making.

For cross-contamination risk in diagnostic reagent preparation, applying pharmaceutical cleaning validation concepts like MACO (Maximum Allowable Carryover) and PDE (Permitted Daily Exposure) ensures that no assay-to-assay contamination occurs in multi-test platforms.

Designing Clinical Trials with Companion Diagnostics

When integrating CDx into oncology trials, trial design must reflect the biomarker’s prevalence, predictive power, and the assay’s availability. In an enrichment design, only biomarker-positive patients are enrolled, maximizing effect size but potentially slowing accrual if prevalence is low. An all-comers design with biomarker-stratified analysis allows exploratory evaluation of biomarker-negative patients.

Adaptive designs can allow for mid-trial modifications based on interim biomarker prevalence data, while basket and umbrella trials can leverage a single assay to assign patients to multiple targeted therapies. For example, a comprehensive NGS panel could identify HER2 amplification, BRAF mutations, and RET fusions for allocation to different arms within the same master protocol.

Operationalizing CDx Testing in Trials

Operational success depends on fast turnaround times (TAT) and consistent assay performance across global sites. Establishing a central testing laboratory can standardize results but may increase logistical complexity for sample shipment. Alternatively, a decentralized model with harmonized local labs requires rigorous cross-validation (≥90% concordance with central lab results).

Consent forms must explicitly mention the use of a companion diagnostic, potential incidental findings (e.g., germline BRCA mutations), and data sharing for regulatory purposes. Clinical trial management systems should track test performance metrics, including invalid rates, re-testing frequency, and median TAT.

Reference operational SOPs, such as those available on PharmaGMP.in, to streamline documentation for audits and inspections.

Regulatory Submission and Approval Pathways

The drug and the CDx are often submitted concurrently in a coordinated regulatory package. The FDA requires a premarket approval (PMA) for most CDx devices, while the EMA mandates a CE marking under IVDR rules. Bridging studies may be required if the pivotal trial assay differs from the commercial version, with statistical comparability set at ≥90% concordance.

Post-approval, CDx manufacturers may need to expand the assay’s indications, such as adding ctDNA detection to a tissue-based test. These modifications typically require supplemental PMA submissions or revised technical documentation under IVDR.

Conclusion: Making CDx Work for Precision Oncology

Effective companion diagnostics require early and integrated planning between drug and diagnostic development teams. By aligning regulatory strategies, ensuring rigorous analytical validation, and building operational workflows that can deliver results rapidly and reproducibly, CDx can significantly increase the probability of trial success and regulatory approval. The reward is a therapy that reaches the right patients faster, with robust evidence that the biomarker truly guides treatment benefit.

Designing Oncology Trials That Use Genomic Alterations for Eligibility

Why use genomic alterations as inclusion criteria—and when?

Genomic inclusion criteria align the investigational therapy’s mechanism of action with patients most likely to benefit. Instead of enrolling “all‑comers,” you prospectively select participants with actionable alterations—EGFR exon 19 deletions, ALK/RET fusions, BRAF V600E, BRAFV600K, BRCA1/2 pathogenic variants, IDH1 R132H, NTRK fusions, and so on—so that the observed treatment effect reflects target engagement rather than chance. This approach increases biological signal, reduces sample size, and can support expedited pathways when effect sizes are large. That said, “genomics‑only” eligibility is not automatically optimal. In tumors with low alteration prevalence or uncertain predictive value, overly narrow criteria can cripple accrual, inflate screen‑fail rates, and introduce spectrum bias (you only study patients with extensive prior testing and access). A principled decision requires: (1) strong translational evidence that the alteration is predictive, not merely prognostic; (2) an analytical pipeline capable of reliably detecting the alteration; and (3) a trial design that preserves internal validity while remaining feasible across regions and labs.

Start from a target–biomarker hypothesis map. For a selective RET inhibitor, for example, a primary cohort might require confirmed RET fusions by RNA‑based NGS or IHC‑triage plus orthogonal RNA confirmation, with exploratory cohorts for high‑copy RET amplifications. For DNA damage response agents, you may specify pathogenic loss‑of‑function variants in BRCA1/2, PALB2, or ATM, and predefine how variants of unknown significance (VUS) are handled (usually excluded unless centrally adjudicated). “Eligibility ≠ diagnosis”: you must encode bioinformatics rules in the protocol—what variant callers are allowed, minimum read depth, and whether subclonal variants from circulating tumor DNA (ctDNA) count toward inclusion.

From biomarker idea to eligibility language: writing precise, auditable criteria

Eligibility language should be specific enough for monitors and inspectors to verify, yet feasible for sites to implement quickly. Replace vague phrases like “genomic evidence of target activation” with operational definitions. Example: “Presence of an ALK rearrangement detected by an RNA‑based NGS assay with (a) minimum 50,000 total mapped reads, (b) paired‑end strategy, (c) fusion junction coverage ≥10 reads, and (d) reporting by a CLIA‑certified/ISO‑15189 laboratory; FISH‑positive cases are eligible if the break‑apart signal proportion is ≥15% in ≥50 evaluable nuclei.” For ctDNA‑based inclusion, pre‑specify variant allele frequency (VAF) thresholds—e.g., “EGFR L858R with VAF ≥0.5% by validated digital PCR or hybrid‑capture NGS, limit of detection (LOD) ≤0.2%.”

To guide investigators, include a concise matrix linking tumor type, alteration, test method, and line of therapy. Also define time windows: “genomic result within 90 days of consent” and whether archived tissue is acceptable. If multiple platforms are permitted, add a comparability statement (e.g., concordance ≥90% in a bridging study) and a central confirmation workflow for discordant cases. A short “ineligible but interesting” pathway helps capture patients with near‑miss results (e.g., VAF 0.4%) into exploratory cohorts without contaminating the primary efficacy population. For reference SOP templates and checklists, many teams adapt materials similar to those found on PharmaSOP.in to keep site screening consistent and auditable.

Assay strategy and validation: LOD, LOQ, and practical cutoffs that survive inspection

Analytical performance drives who gets in. Before first‑patient‑in, document the assay’s sensitivity, specificity, and reportable range, and map those parameters to inclusion thresholds. Use a short, inspector‑friendly table like the one below to anchor your protocol and lab manual. Include illustrative values if proprietary data can’t be published verbatim in the protocol; keep full validation in the laboratory appendix/TMF.

Why mention MACO/PDE in a clinical protocol? Inspectors look for a complete chain of control when diagnostics interface with IMP prep or shared cleanrooms. Even when your CDx is external, a brief cross‑reference to cleaning validation and permissible daily exposure (PDE) helps show risk‑aware governance. Finally, predefine variant classification rules (ACMG/AMP), how tumor purity affects interpretation, and how copy‑number thresholds translate to “amplified” status—e.g., “ERBB2 copy number ≥6 by NGS or ratio ≥2.0 by FISH.”

Choosing the right design: enrichment, basket, umbrella, and platform options

Enrichment RCTs (biomarker‑positive only) maximize effect size and can power overall survival (OS) with fewer patients. They’re ideal when the biomarker is strongly predictive and prevalent (e.g., EGFR mutations in non‑smokers with NSCLC). Basket trials test one drug across multiple histologies with a shared alteration (e.g., NTRK fusions), using parallel cohorts and Bayesian borrowing to stabilize estimates in rare tumors. Umbrella trials test multiple drugs within a single tumor type, randomized by genomic subtype. Platform/master protocols maintain a permanent backbone with arms opening/closing as signals emerge—useful when the genomic landscape shifts rapidly.

Statistical planning hinges on alteration frequency and expected effect size. For a single‑arm basket cohort with historical control ORR 10% and expected ORR 30%, a Simon two‑stage design (α=0.05, 1‑β=0.8) might enroll 15 in stage 1 (stop if ≤2 responses), expanding to 35. For RCTs, stratify by key covariates (ECOG, disease burden) and enforce central confirmation of biomarker status before randomization. Multiplicity control is essential when testing several alterations; prespecify a hierarchical sequence or use alpha‑sharing across cohorts. Keep interim futility rules transparent—e.g., “stop a cohort if posterior P(ORR ≥25%) <10% after 12 evaluable patients.”

Operations: screening logistics, consent, data flow, and query resistance

Real‑world screening is the hardest part. Build a screening cascade: (1) prescreen with existing reports; (2) reflex NGS on archival tissue; (3) if inadequate, repeat biopsy or ctDNA; (4) central review/adjudication; (5) slot reservation. Encode turnaround time targets (e.g., tissue NGS ≤14 calendar days; ctDNA ≤7 days) and escalation if breached. Consent must explicitly address re‑biopsy risks, germline findings (for HRR pathways), and data sharing for variant reclassification. Include a “return of results” plan and a path for incidental actionable germline variants (e.g., referral to genetics).

Data collection: require upload of variant call files (VCF) or structured reports, not just PDFs. Capture bioinformatics pipeline versions to ensure analyses remain reproducible. To avoid endless queries, provide CRF fields for: sample type (tissue/ctDNA), tumor purity %, read depth, VAF, fusion junction reads, and assay platform. A small on‑protocol “bioinformatics glossary” (hotspot vs non‑hotspot, indels vs SVs) helps harmonize multi‑country sites. Build screen‑fail logs with reasons (no alteration, insufficient tissue, below VAF cutoff) to refine feasibility assumptions mid‑trial.

Regulatory expectations and real‑world examples

When a companion diagnostic (CDx) is intended, regulators expect a tightly coupled drug–diagnostic package: analytical validation, clinical validation, and bridging if multiple assays will be allowed commercially. For supportive context and up‑to‑date definitions, see the U.S. agency’s overview of CDx concepts at the FDA. Common real‑world patterns include: (1) tissue‑based CDx for initial approval with a post‑marketing commitment to add ctDNA; (2) centralized testing in pivotal studies followed by decentralization via a ring study; and (3) prespecified retesting rules for discordant local vs central results. In the EU, scientific advice often focuses on the clinical utility of the chosen cutoff (e.g., TMB ≥10 mut/Mb) and assay harmonization across notified bodies.

Case vignette (hypothetical but representative): a selective KRAS G12C inhibitor uses inclusion “KRAS p.G12C by tissue NGS or ctDNA VAF ≥0.5% with LOD ≤0.2%.” Early cohorts showed similar responses for VAF ≥1% and 0.5–1.0%, supporting the ctDNA path. However, false positives clustered around 0.2–0.3% VAF from fragmented samples, prompting a protocol amendment to require orthogonal confirmation (amplicon‑based ddPCR) for VAF 0.3–0.49%. This change cut screen‑fails due to discordance by half while preserving accrual velocity.

Equity, access, and bias mitigation in genomics‑based eligibility

Genomic eligibility can inadvertently exclude patients from under‑resourced settings or minority populations with lower test access. Bake equity into the design: reimburse molecular testing, allow ctDNA for patients without safe biopsy options, and include mobile phlebotomy or courier support. Stratify analyses by testing modality to ensure ctDNA‑included participants do not have systematically different outcomes due to lower sensitivity at low tumor burden. Provide translated consent forms and community‑site training to avoid “academic‑center‑only” recruitment. Finally, add sensitivity analyses that drop cases with borderline VAF or sub‑threshold depth; if conclusions hold, you’ll have stronger external validity.

Putting it all together: a step‑by‑step checklist and a mini‑case study

Checklist: (1) Define the predictive biomarker and clinical context; (2) Lock analytical specs (LOD/LOQ, depth, fusion reads) and write eligibility as auditable rules; (3) Choose design (enrichment, basket, umbrella/platform) and simulate power under realistic prevalence; (4) Stand up screening logistics with defined TATs and adjudication; (5) Predefine handling for VUS, borderline VAF, and discordant results; (6) Implement equity measures and track screen‑fail reasons; (7) Archive assay versions, pipelines, and central review decisions in the TMF;

Mini‑case (RET fusion basket): Multi‑tumor basket with primary endpoint ORR. Inclusion: RET fusions by RNA‑NGS, ≥10 junction reads, ctDNA allowed with confirmatory RNA‑NGS if VAF 0.3–0.49%. Stage 1 (n=14): stop if ≤2 responses. Results: 6 responses → expand to n=35. Subgroup ORR (illustrative): thyroid 60% (n=10), lung 53% (n=15), pancreas 22% (n=10). Safety acceptable; RP2D maintained. The protocol’s tight fusion criteria prevented misclassification from read‑through events and allowed a clean efficacy signal, enabling a registrational strategy with a confirmatory cohort.

Conclusion: precision eligibility that’s scientific, feasible, and inspection‑ready

Using genomic alterations as inclusion criteria isn’t merely adding an NGS line to the protocol—it’s a system of analytical rigor, operational discipline, and ethical foresight. Write eligibility that laboratories can execute reproducibly, anchor cutoffs in validated LOD/LOQ, select designs that respect prevalence and effect sizes, and build logistics that make testing accessible for all eligible patients. With those pieces in place—and transparent documentation that regulators can follow—you’ll deliver trials that are faster, fairer, and far more likely to reveal the true value of precision oncology.